Oncopeptides invited to present at ASH in December
Oncopeptides today announces that an evaluation of the activity of two peptide drug conjugates (PDCs) developed by Oncopeptides in relapsed or refractory Acute Myeloid Leukemia has been accepted as a poster and will be presented at the 66th annual American Society of Hematology (ASH) Meeting and Exposition. The conference takes place in San Diego, California between December 7-10.
The study, conducted in collaboration with the Institute for Molecular Medicine Finland, FIMM, explores the preclinical effectiveness of two drugs based on Oncopeptides unique and proprietary PDC platform, melflufen and candidate drug OPDC3, for treating acute myeloid leukemia (AML) especially in cases where one of the standard treatments, venetoclax, has stopped working. Both drugs target cancer cells in a unique way and have shown promising results in laboratory tests with venetoclax-resistant AML preclinical models.
ASH is the world’s largest professional hematologic society serving both clinicians and scientists around the world who are working to conquer blood diseases.
“The findings could support the development of new treatment options for AML patients who have limited alternatives based on the PDC platform,” says Caroline Heckman, PhD, Research Director, FIMM. “We are happy to have been selected to present our findings at ASH and look forward to the opportunity.”
Find more details about the abstract and presentation below. The abstract including key data has been published and is available through this link.
For more information about ASH Annual Meeting and Exposition, click here.
| Title | Efficacy of the Peptide Drug Conjugates Melflufen and OPDC3 in Venetoclax Resistant Acute Myeloid Leukemia. |
| Publication Number | 1548 |
| Presenting author | Juho Miettinen, PhD, senior researcher at FIMM. |
| Program | Oral and Poster Abstracts |
| Time | Saturday, December 7, 2024, 5:30 PM-7:30 PM |
| Session | 618. Acute Myeloid Leukemias: Biomarkers and Molecular Markers in Diagnosis and Prognosis: Poster I |
Investor Q&A
What is this?
Oncopeptides has had a poster accepted and is invited to present it at the ASH Annual Meeting and Exposition in December.
What is a poster?
In the world of medicine, it is a means of academic communication that allows researchers, scholars, and clinicians to present their research findings or clinical case reports in a visual and succinct format. Posters are used at medical conferences as a form of scholarly output alongside oral presentations and published abstracts.
The poster is usually designed to fit a specific size requirement and is displayed in a designated area during the conference. Attendees can view the posters at their leisure, and there are often dedicated sessions when the authors stand by their poster to discuss their work with other conference participants.
The main advantages of a poster presentation are the opportunity for personal interaction and detailed discussion with interested peers, and the chance to receive feedback and potentially form collaborations.
How does the selection process look like?
Typically, more than 5,000 scientific abstracts are submitted each year and more than 3,000 abstracts are accepted for oral and poster presentations through an extensive peer review process.
Will the poster or presentation be available to the public?
The poster will be published on Oncopeptides web site following the congress. An abstract including key results is already available.